Home > Insider Trading > Filing (0001181431-11-057709)

Filing Details

Accession Number:: 0001181431-11-057709
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-11-28 16:27:45
Reporting Period:: 2011-11-23

Filing Date:: 2011-11-28
Accepted Time:: 2011-11-28 16:27:45
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178711	Transcept Pharmaceuticals Inc	TSPT	Pharmaceutical Preparations (2834)	330960223

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1454280	P Thomas Soloway	C/O Transcept Pharmaceuticals, Inc. 1003 W. Cutting Blvd, Suite 110 Point Richmond CA 94804	Svp, Operations And Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-11-23	13,600	$2.68	13,600	No	4	M	Direct
Common Stock	Disposition	2011-11-23	13,600	$7.87	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee stock option (right to buy)	Disposition	2011-11-23	13,600	$0.00	13,600	$2.68

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
63,900		2021-08-24	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	10,401	Indirect	See footnote
Common Stock	20,833	Indirect	See footnote

Footnotes

Shares held directly by the Reporting Person has been reduced by 2,239 shares that were transferred on September 7, 2011 to the Thomas J. Soloway Revocable Family Trust for which the Reporting Person serves as trustee.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 13, 2011.
The sales price reported in column 4 of Table 1 represents the weighted average sales price of the shares purchased ranging from $8.05 to $7.72 per share. Upon request of the commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Shares held directly by the Thomas J. Soloway Revocable Family Trust ("the "Family Trust") for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the Family Trust except to the extent of his pecuniary interest therein. The number of shares include 2,239 shares that were transferred on September 7, 2011 directly from the Reporting Person.
Shares held directly by the Thomas J. Soloway 2003 Irrevocable Trust (the "2003 Trust") for which the Reporting Person's spouse serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the 2003 Trust except to the extent of his pecuniary interet therein.
Fifty percent of the option vests upon approval by the Federal Food and Drug Administration of Intermezzo (TM) and the remaining fifty percent vests on the first anniversary of any such approval; provided in each case, such approval occurs no later than August 24, 2013. Approval by the Federal Food and Drug Administration of Intermezzo (TM)occurred on November 23, 2011.